Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin?s lymphoma

Antonella Cingolani, Lorenza Torti, Carmela Pinnetti, K. D G Donati, Rita Murri, Evelina Tacconelli, Luigi Maria Larocca, Luciana Teofili

Research output: Contribution to journalArticlepeer-review

Abstract

In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.

Original languageEnglish
Pages (from-to)2408-2412
Number of pages5
JournalAIDS (London, England)
Volume24
Issue number15
DOIs
Publication statusPublished - Sep 24 2010

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin?s lymphoma'. Together they form a unique fingerprint.

Cite this